source
- STAT+: Pharmalittle: We’re reading about a Roche lung cancer drug, a Bristol CAR-T trial death, and moreBristol Myers Squibb reported that one patient died after receiving its investigational CAR-T therapy in an early autoimmune trialSTAT · 14d ago↗ source
- Roche's KRAS G12C inhibitor cuts death risk by 44% versus Amgen and BMS in lung cancer trialAt the European Society for Medical Oncology meeting in Madrid, Roche presented data on its next‑generation KRAS G12C inhibitor in non‑small cell lung cancer. In a head‑to‑head study against compa…